SCHEMBL25856473

SCHEMBL25856473

CCC1CCN(C2CCN(CC)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.38
CHRM4 P08173 1/20 0.37
ACHE P22303 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
OPRM1 P35372 1/20 0.36
OPRL1 P41146 1/20 0.36
MEN1 O00255 1/20 0.35
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24838817 0.93 KMT2A (0.42) KMT2ASMN1; SMN2CHRM4ACHEHRH3
SCHEMBL178287 0.87 SMN1; SMN2 (0.46) KMT2ASMN1; SMN2ACHEHRH3
SCHEMBL12605203 0.84 MEN1 (0.42) KMT2AHRH3OPRM1OPRL1MEN1
Fluoride SCHEMBL29252276 0.84 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2ACHEHRH3KDM4E
SCHEMBL26329494 0.84 OPRL1 (0.48) KMT2ASMN1; SMN2CHRM4HRH3OPRM1
SCHEMBL27258578 0.83 KMT2A (0.33) KMT2ASMN1; SMN2HRH3MEN1
SCHEMBL13179268 0.83 KMT2A (0.44) KMT2ASMN1; SMN2CHRM4ACHEMEN1
SCHEMBL11919058 0.82 KMT2A (0.56) KMT2ASMN1; SMN2CHRM4ACHEOPRM1
SCHEMBL11919045 0.82 KMT2A (0.56) KMT2ASMN1; SMN2CHRM4ACHE
SCHEMBL24865954 0.81 KMT2A (0.42) KMT2ASMN1; SMN2CHRM4ACHEHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023242598-A1 BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2023-12-21 WO disclosed
WO-2023242597-A1 BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2023-12-21 WO disclosed
WO-2023131167-A1 COMPOUND FOR INHIBITING AND DEGRADING IRAK4, AND PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF 海思科医药集团股份有限公司 2023-07-13 WO disclosed